Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Gemcitabine

5

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

2
Last update : 17/08/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.
Journal of cancer research and clinical oncology 2011 Oct;137;1469-75 2011 Oct
An autopsy case of acute pulmonary toxicity associated with gemcitabine.
Internal medicine (Tokyo, Japan) 2003 Oct;42;1022-5 2003 Oct
Diffuse alveolar damage in a patient treated with gemcitabine.
The European respiratory journal 1998 Feb;11;504-6 1998 Feb
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
Cancer 1997 Jul 15;80;286-91 1997 Jul 15

Powered by

  • ^
  • Contact
  • Cookies
  • About